WO1998032423A1 - Microspheres a liberation prolongee, leur production et utilisation - Google Patents

Microspheres a liberation prolongee, leur production et utilisation Download PDF

Info

Publication number
WO1998032423A1
WO1998032423A1 PCT/JP1998/000339 JP9800339W WO9832423A1 WO 1998032423 A1 WO1998032423 A1 WO 1998032423A1 JP 9800339 W JP9800339 W JP 9800339W WO 9832423 A1 WO9832423 A1 WO 9832423A1
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
salt
physiologically active
active peptide
acid
Prior art date
Application number
PCT/JP1998/000339
Other languages
English (en)
Inventor
Shigeru Kamei
Tsutomu Ohta
Akira Saikawa
Yasutaka Igari
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU56783/98A priority Critical patent/AU5678398A/en
Publication of WO1998032423A1 publication Critical patent/WO1998032423A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to sustained-release microspheres comprising a physiologically active peptide, a sustained-release preparation comprising the microspheres, and a method of producing the microspheres.
  • sustained-release preparation comprising a physiologically active peptide possessing LH-RH antagonist activity or a salt thereof and a biodegradable polymer having a free carboxyl group at one end, and a method of its production.
  • control release drug composition comprising a water-insoluble adduct salt of a water-soluble peptide such as an LH-RH derivative converted by using a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as pamoic acid, tannic acid or stearic acid, or the like, and a non-toxic water-insoluble acid such as
  • Japanese Patent Unexamined Publication No. 68511/1991 describes a method of producing a sustained-release microparticle formulation wherein a microparticles is formed by dispersing a drug solution into a polymer solution in which the drug compound is insoluble, followed
  • Japanese Patent Unexamined Publication No. 221855/1993 discloses a process for the production of a pharmaceutical composition for the sustained and controlled release of a peptide, obtained in the form of microsphere of a biodegradable polymeric material incorporating the peptide which comprises initially converting a water-soluble peptide into a water-insoluble peptide, followed by preparing an o/w emulsion, and extracting the organic solvent for the polymeric material in an excess of aqueous medium.
  • Japanese Patent Unexamined Publication No. 340543/1994 describes a sustained-release preparation wherein the embonic acid (pamoic acid) or ascorbic acid salt of a peptide as an active ingredient in a matrix of a polylactide having a lactide/glycolide molar ratio of 100:0 to 40:60, a molecular weight of 10,000 to 200,000, and a degree of polydispersion of 1.7 to 3.0, suggesting that embonic acid and ascorbic acid are useful as stabilizers in peptides in polylactides.
  • 095/15767 describes the embonic acid salt (pamoic acid) of cetrorelix (LH-RH antagonist) and a method of its production, stating that the duration of action was about the same as that of peptide embonate in a biologically degradable polymer.
  • a pamoic acid salt of a physiologically active peptide in a formulation enables to stabilize the physiologically active peptide or to control its release; however, there have been absolutely no reports of a composition wherein a fine and minute pamoic acid salt of a physiologically active peptide is formed in the presence of a biodegradable polymer, or a three-component salt comprising a physiologically active peptide, a pamoic acid and a biodegradable polymer, and a composition containing it.
  • sustained-release preparations obtained by these published methods are unsatisfactory in view of clinical application.
  • a sustained-release microsphere comprising a physiologically active peptide at high contents, and capable of controlling its release rate, can be produced by emulsification of a solution of a physiologically active peptide and a solution of a pamoic acid or a salt thereof by a biodegradable polymer.
  • a physiologically active peptide can be incorporated at high contents by emulsification of a physiologically active peptide having basic groups capable of forming salts with a pamoic acid, a pamoic acid or a salt thereof and a biodegradable polymer in a molecular dispersion like in solution to form a fine pamoic acid salt of the physiologically active peptide of about 0.01 to about 10 ⁇ in particle size not later than solvent removal, and producing a microsphere containing the pamoic acid salt, unlike conventional methods involves pre-conversion of physiologically active peptide to pamoic acid salt in the absence of polymer.
  • the present inventors also found in the case of a peptide having not less than 2 basic groups that a pamoic acid/physiologically active peptide ratio differing from that of microspheres produced by conventional methods which contain a previously prepared pamoic acid salt of a physiologically active peptide, and that the physiologically active peptide release rate can be controlled by the decomposition rate of the biodegradable polymer when the physiologically active peptide is allowed to form a complex or salt with both a pamoic acid and a biodegradable polymer having a free carboxyl group, and a microsphere containing it is prepared.
  • the present invention provides:
  • a method of producing a sustained-release microsphere which comprises emulsification of a physiologically active peptide or a salt thereof wherein the salt is not a pamoic acid salt and a pamoic acid or an alkaline metal salt thereof with a biodegradable polymer;
  • physiologically active peptide is a peptide having basic groups capable of forming salts with a pamoic acid
  • physiologically active peptide is a peptide having not less than 2 basic groups capable of forming salts with a pamoic acid;
  • physiologically active peptide is an LH-RH agonist;
  • physiologically active peptide is an LH-RH antagonist
  • physiologically active peptide is a 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg- Pro-NH-C 2 Hs or a salt thereof;
  • the physiologically active peptide is a 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg- Pro-NH-C 2 Hs acetate;
  • biodegradable polymer is a polymer of ⁇ -hydroxy carboxylic acids
  • sustained-release microsphere which is obtainable by the method according to (1);
  • the sustained-release microsphere which comprises an about 0.01 to about 10 ⁇ m particle size of a pamoic acid salt of the physiologically active peptide and a biodegradable polymer;
  • a sustained-release microsphere which comprises a complex or a salt formed by a physiologically active peptide, a pamoic acid or a salt thereof and a biodegradable polymer;
  • a sustained-release microsphere which comprises not more than about 0.8 mol of pamoic acid to 1 mol of physiologically active peptide
  • the sustained-release microsphere according to (32), which comprises about 0.3 to about 0.7 mol of the pamoic acid to 1 mol of the physiologically active peptide is contained; (34) The sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is a physiologically active peptide having basic groups capable of forming salts with a weak acid of not less than pKa4.0; (35) The sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is a peptide having basic groups capable of forming salts with a pamoic acid;
  • sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is a peptide having not less than 2 basic groups capable of forming salts with a pamoic acid;
  • sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is an LH-RH antagonist;
  • sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is a 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH- C 2 H 5 or a salt thereof;
  • sustained-release microsphere according to any one of (29) to (32), wherein the physiologically active peptide is a 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH- C 2 H 5 acetate;
  • polymer of ⁇ -hydroxy carboxylic acids is a lactic acid/glycolic acid polymer
  • sustained-release microsphere according to any one of (29) to (32), wherein a ratio of the pamoic acid or a salt thereof in the sustained-release microsphere is about 0.1 to about 25 wt% of the sustained-release microsphere;
  • sustained-release microsphere according to any one of (29) to (32), wherein a ratio of the biodegradable polymer in the sustained-release microsphere is about 15 to about 85 wt% of the sustained-release microsphere;
  • a sustained-release preparation which comprises the microsphere according to any one of (29) to (32);
  • a sustained-release preparation which comprises the microsphere according to (37) or (38);
  • sustained-release preparation according to (55) which is a treating or preventive agent for prostatic cancer, prostatic hypertrophy, endometriosis, hysteromyoma. dysmenorrhea, precocious puberty or breast cancer, or a contraceptive agent.
  • physiologically active peptides used in the method of the present invention may be any peptides which are capable of forming a salt with a pamoic acid and showing physiologically activities.
  • the peptide are a peptide having about 300 to about 40,000, preferably about 400 to 30,000, furthermore preferably about 500 to 20,000 molecular weight, and so on.
  • Such peptides may preferably have basic groups which are capable of forming a salt with a weak acid of not less than pKa 4.0 (e.g. carbonic acid, bicarbonic acid, bornic acid, C ⁇ _ 3 lower alkane-monocarbonic acid, etc.).
  • a weak acid e.g. carbonic acid, bicarbonic acid, bornic acid, C ⁇ _ 3 lower alkane-monocarbonic acid, etc.
  • physiologically active peptide When the physiologically active peptide has some basic groups in its molecule, so long as at least one basic group is capable of forming a salt with a pamoic acid, other groups may form salts.
  • Physiologically active peptides having not only basic groups but also acidic groups which are free or forming salts may be involved in the physiologically active peptide of the present invention, so long as they are capable of forming salts with a pamoic acid.
  • the representative examples of activities of the physiologically peptides are hormone activity, etc.
  • the physiologically active peptides may be natural products, synthesized products, half-synthesized products or gene products, and furthermore may be analogs and/or derivatives thereof.
  • the mechanism of these physiologically active peptides may be agonistic or antagonistic.
  • physiologically active peptides examples include luteinizing hormone-releasing hormone (sometimes referred to as LH-RH, gonadotropin-releasing hormone or Gn- RH) , insulin, somatostatin, somatostatin derivative
  • GH growth hormones
  • G-RH growth hormone-releasing hormones
  • EPO erythropoietin
  • ACTH adrenocorticotropic hormone
  • ACTH derivatives e.g., ebiratide
  • MSH melanocyte-stimulating hormone
  • TRH thyrotropin-releasing hormone
  • TSH thyroid-stimulating hormone
  • LH luteinizing hormone
  • FSH follicle-stimulating hormone
  • vasopressin vasopressin derivative
  • oxytocin calcitonin
  • glucagon gastrin
  • secretin pancreozymin
  • cholecystokinin angiotensin
  • HCG human chorionic gonadotropin
  • tumor necrosis factor TNF
  • colony- stimulating factors e.g., CSF, GCSF, GMCSF, MCSF
  • motilin e.g., CSF, GCSF, GMCSF, MCSF
  • motilin e.g., CSF, GCSF, GMCSF, MCSF
  • motilin e.g., CSF, GCSF, GMCSF, MCSF
  • motilin e.g., dynorphin, bombesin, neurotensin, caerulein, bradykinin, atrium sodium-excretion increasing factor
  • nerve growth factor NGF
  • cell growth factors e.g., EGF, TGF- ⁇ , TGF- , PDGF, acidic FGF, basic FGF
  • nerve nutrition factors e.g., NT-3, NT-4, CNTF, GDNF, BDNF
  • the physiologically active peptides include pharmacologically acceptable salts.
  • salts are salts formed with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid and bornic acid) or salts formed with organic acids (e.g., carbonic acid, bicarbonic acid, succinic acid, acetic acid, propionic acid and trifluoroacetic acid) , when the physiologically active peptide has a basic group such as the amino group.
  • inorganic acids e.g., hydrochloric acid, sulfuric acid, nitric acid and bornic acid
  • organic acids e.g., carbonic acid, bicarbonic acid, succinic acid, acetic acid, propionic acid and trifluoroacetic acid
  • the salts are salts formed with inorganic bases (e.g., alkaline metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium) or salts formed with organic base compounds (e.g., organic amines such as triethylamine, and basic amino acids such as arginine), when the physiologically active peptide has an acidic group such as the carboxy group. And, the physiologically active peptide may form a metal complex compound (e.g., copper complex compound, zinc complex compound).
  • a pamoic acid salt of the physiologically active peptide is excluded from a salt of the physiologically active peptide used as a material for the method of production of the present invention.
  • Preferable physiologically active peptides for the present invention include, for example, LH-RH analogues effective against diseases dependent on LH-RH or hormones induced thereby, such as prostatic cancer, prostatic hypertrophy, endometritis, hysteromyoma, dysmenorrhea, precocious puberty and breast cancer, and as contraceptives, and salts thereof, and somatostatin derivatives effective against diseases dependent on growth hormones and hormones induced thereby, and gastrointestinal diseases such as digestive ulcers, and salts thereof.
  • LH-RH analogs or salts thereof are peptides described in Treatment with GnRH analogs: Controversies and perspectives. The Parthemon Publishing Group Ltd., 1996; and Japanese Patent Unexamined Publication Nos. 503165/1991, 101695/1991, 97334/1995 and 259460/1996 and so on.
  • the preferable examples of the physiologically active peptide having LH-RH antagonistic activity are a physiologically active peptide represented by the formula: X-D2Nal-D4ClPhe-D3Pal-Ser-A-B-Leu-C-Pro-DAlaNH 2 ( la) wherein X is N(4H2-furoyl)Gly or NAc, A is a residue selected from NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz), B is a residue selected from DLys(Nic), DCit, DLys(AzaglyNic) , DLys(AzaglyFur) , DhArg(Et 2 ), DAph(Atz) and DhCi, C is a residue selected from Lys(Nisp), Arg and hArg(Et2), and so on «
  • physiologically active peptide having LH-RH antagonistic activity are physiologically active peptides described in US Patent No. 5,580,957 and so on. These peptides can be prepared by the methods described in the above-mentioned references or publications or similar methods.
  • physiologically active peptide having LH-RH agonistic activity are a physiologically active peptide represented by the formula: 5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z (lb) wherein Y is a residue selected from DLeu, DAla, DTrp, Dser(tBu), D2Nal and DHis(lmBZl), Z is NH-C 2 H 5 or Gly-NH 2 , and so on. Of these peptides, the peptide wherein Y is DLeu and Z is NH-C 2 H 5 is preferred.
  • peptides can be prepared by the methods described in the above-mentioned references or publications or similar methods. Specific examples of the somatostatin derivatives or a salt thereof are described in Proceedings of National Academy of Science, USA, 93, 12513-12518, 1996 or references cited. And, examples of the somatostatin derivatives which are selectively useful for cancer are i 1
  • DPhe-Cys-Tyr-DTrp-Lys-Cys-ThrNH2 US Patent No. 5,480,870, European Patent Publication No. 50568, and so on.
  • Other preferable examples of the somatostatin derivatives are sandostatin (US Patent Nos. 4,087,390, 4,093,574, 4,100,117 and 4,253,998.) and so on.
  • physiologically active peptides having one basic group capable of forming a salt with a pamoic acid are a physiologically active peptide or a salt thereof, represented by the formula [lb] having a LH-RH agonistic activity and so on.
  • physiologically active peptides having not less than 2 basic groups capable of forming salts with a pamoic acid are a physiologically active peptide, or a salt thereof, represented by the formula (la) having a LH-RH antagonistic activity.
  • the physiologically active peptide represented by the formula (lb) can be also used.
  • physiologically active peptide are 5-oxo-Pro-His-Trp-Ser- Tyr-DLeu-Leu-Arg-Pro-NH-C 2 Hs or a salt thereof (particularly, acetate, etc.).
  • NMeAph(Atz) N-methyl-[ 5 ' - ( 3 ' -amino-1 ' H-l ' , 2 ' 4 ' - triazolyl) ]phenylalanine residue
  • Lys(Nisp) ( epsilon-N-isopropyl ) lysine residue hArg(Et 2 ) (N,N' -diethyl)homoarginine residue
  • DHis(lmBzl) D-(7r -benzyl)histidine residue Abbreviations for other amino acids are based on abbreviations specified by the IUPAC-IUB Commission on Biochemical Nomenclature (European Journal of Biochemistry, 138, 9-37, 1984) or abbreviations in common use in relevant fields. When an optical isomer may be present in amino acids, it is of the L-configuration, unless otherwise stated.
  • biodegradable polymers used for the method of the present invention include homopolymers and copolymers, which are synthesized from one or more - hydroxy acids (e.g., glycolic acid, lactic acid, hydroxybutyric acid), hydroxydicarboxylic acids (e.g., malic acid), hydroxytricarboxylic acids (e.g., citric acid) etc., mixtures thereof; poly- ⁇ -cyanoacrylates; polyamino acids (e.g., poly-y-benzyl-L-glutamic acid) and maleic anhydride copolymers (e.g., styrene-maleic acid copolymers) .
  • hydroxy acids e.g., glycolic acid, lactic acid, hydroxybutyric acid
  • hydroxydicarboxylic acids e.g., malic acid
  • hydroxytricarboxylic acids e.g., citric acid
  • poly- ⁇ -cyanoacrylates e.g., polyamino
  • copolymerization may be of the random, block or graft type.
  • a-hydroxy acids, hydroxydicarboxylic acids and hydroxytricarboxylic acids have an optical active center in their molecular structures, they may be of the D-, L- or DL-configuration.
  • a lactic acid/glycolic acid polymer and a poly- ⁇ - cyanoacrylates are preferred, and furthermore a lactic acid/glycolic acid polymer is more preferred.
  • the biodegradable polymer is preferably (1) a biodegradable polymer consisting of a mixture of (A) : a copolymer of a glycolic acid and a hydroxycarboxylic acid represented by the formula:
  • R represents an alkyl group having 2 to 8 carbon atoms and (B): a polylactic acid or (2) a copolymer of lactic acid and glycolic acid.
  • the straight- chain or branched alkyl group represented by R which has 2 to 8 carbon atoms, is exemplified by ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2, 2-dimethylbutyl, 3,3- dimethylbutyl and 2-ethylbutyl.
  • a straight- chain or branched alkyl group having 2 to 5 carbon atoms is used.
  • alkyl groups include ethyl, propyl, isopropyl, butyl and isobutyl. More preferably, R is ethyl.
  • the hydroxycarboxylic acid represented by the formula (II) is exemplified by 2-hydroxybutyric acid, 2- hydroxyvaleric acid, 2-hydroxy-3-methylbutyric acid, 2- hydroxycaproic acid, 2-hydroxyisocaproic acid and 2- hydroxycapric acid, with preference given to 2- hydroxybutyric acid, 2-hydroxyvaleric acid, 2-hydroxy-3- methylbutyric acid and 2-hydroxycaproic acid, with greater preference given to 2-hydroxybutyric acid.
  • the hydroxycarboxylic acid may be of the D-, L- or D,L- configuration
  • glycolic acid copolymerization may be of random, block or graft type. A random copolymer is preferred.
  • the hydroxycarboxylic acid represented by the formula (II) may be a mixture of one or more kinds in a given ratio. With respect to the composition ratio of glycolic acid and the hydroxycarboxylic acid represented by the formula (II) in glycolic acid copolymer (A), it is preferable that glycolic acid account for about 10 to about 75 mol% and hydroxycarboxylic acid for the remaining portion. More preferably, glycolic acid accounts for about 20 to about 75 mol%, and still more preferably about 40 to about 70 mol%.
  • the weight-average molecular weight of the glycolic acid copolymer is normally 2,000 to 100,000, preferably 3,000 to 80,000, and more preferably 5,000 to 50,000.
  • the polydispersity (weight-average molecular weight/number- average molecular weight) of the glycolic acid copolymer is preferably about 1.2 to about 4.0, more preferably about 1.5 to about 3.5.
  • glycolic acid copolymer (A) can be produced by a known process, such as that described in Japanese Patent Unexamined Publication No. 28521/1986.
  • the above-described polylactic acid may be of the D- or L-configuration or a mixture thereof, it is preferable that the ratio of the D-/L-configuration (mol%) falls within the range from about 75/25 to about 20/80.
  • the ratio of the D-/L-configuration (mol%) is more preferably about 60/40 to about 25/75, and still more preferably about 55/45 to about 25/75.
  • the weight-average molecular weight of said polylactic acid is preferably 1,500 to 100,000, more preferably 2,000 to 80,000, and still more preferably 10,000 to 60,000 (more preferably
  • the dispersity of the polylactic acid is preferably about 1.2 to about 4.0, more preferably about 1.5 to about 3.5.
  • ring-opening polymerization of lactide a cyclic dimer of lactic acid
  • polycondensation of lactic acid two methods are known: ring-opening polymerization of lactide (a cyclic dimer of lactic acid) and polycondensation of lactic acid.
  • Glycolic acid copolymer (A) and polylactic acid (B) are used in a mixture wherein the (A)/(B) ratio (% by weight) falls within the range from about 10/90 to about 90/10.
  • the emulsification ratio (% by weight) is preferably about 20/80 to about 80/20, and more preferably about 30/70 to about 70/30.
  • drug release duration can be shortened by decreasing the molecular weight of polylactic acid mixed or increasing the emulsification ratio (A)/(B).
  • Drug release duration can also be adjusted by altering the kind and content ratio of hydroxycarboxylic acid represented by the formula (II).
  • the biodegradable polymer used is a polylactic acid or lactic acid/glycolic acid polymer
  • its composition ratio (lactic acid/glycolic acid) (mol%) is about 100/0 to about 40/60, preferably about 100/0 to about 45/55, more preferably about 100/0 to about 50/50.
  • the weight-average molecular weight of the above- described lactic acid/glycolic acid polymer is preferably about 3,000 to about 100,000, more preferably about 5,000 to about 80,000.
  • the dispersity of the lactic acid/glycolic acid polymer is preferably about 1.2 to about 4.0, more preferably about 1.5 to about 3.5.
  • the decomposition/elimination rate of a lactic acid/glycolic acid polymer varies widely, depending on composition or molecular weight.
  • Drug release duration can be extended by lowering the glycolic acid ratio or increasing the molecular weight, since decomposition/elimination is usually delayed as the glycolic acid ratio decreases.
  • drug release duration can be shortened by increasing the glycolic acid ratio or decreasing the molecular weight.
  • a long-term (e.g., 1 to 6 months, preferably 1 to 4 months) sustained-release preparation it is preferable to use a lactic acid/glycolic acid polymer whose composition ratio and weight-average molecular weight fall in the above- described ranges.
  • Weight-average molecular weight, number-average molecular weight and dispersity are polystyrene-based molecular weights and dispersity determined by gel permeation chromatography (GPC) with 9 polystyrenes as reference substances with weight-average molecular weights of 120,000, 52,000, 22,000, 9,200, 5,050, 2,950, 1,050, 580 and 162, respectively. Measurements were taken using a GPC column KF804L x 2 (produced by Showa Denko) and an RI monitor L-3300 (produced by Hitachi, Ltd.), with chloroform as a mobile phase.
  • GPC gel permeation chromatography
  • number- average molecular weight was calculated by dissolving the biodegradable polymer in an acetone-methanol mixed solvent, and titrating this solution with an alcoholic solution of potassium hydroxide with phenolphthalein as an indicator, to determine the terminal carboxyl group content.
  • This molecular weight is hereinafter referred to as number- average molecular weight based on terminal group titration. While the number-average molecular weight based on terminal group titration is an absolute value, the number- average molecular weight based on GPC measurement is a relative value that may vary depending on various analytical conditions (e.g., kind of mobile phase, kind of column, reference substance, slice width chosen, baseline chosen); it is therefore difficult to have an absolute numerical representation of the latter.
  • the number-average molecular weight based on GPC measurement and that based on terminal group titration almost agree with each other.
  • This fact for the lactic acid-glycolic acid polymer means that the number-average molecular weight based on terminal group titration falls within the range from about 0.5 to about 2 times, preferably from about 0.7 to about 1.5 times, the number- average molecular weight based on GPC measurement.
  • the lactic acid-glycolic acid polymer for the present invention can be produced by catalyst-free poly- condensation from lactic acid and glycolic acid (Japanese Patent Unexamined Publication No. 28521/1986), or ring- opening polymerization from lactide, glycolide etc. using a catalyst (Encyclopedic Handbook of Biomaterials and Bioengineering Part A: Materials, Volume 2, Marcel Dekker, Inc., 1995).
  • the polymer synthesized by ring- opening polymerization is usually a polymer having no carboxyl groups
  • a polymer obtained by chemically treating the above-described polymer to provide a terminal free carboxyl group Journal of Controlled Release, Vol. 41, pp. 249-257, 1996) can also be used.
  • lactic acid-glycolic acid polymer having a free carboxyl group at one end can be readily produced by known methods (e.g., catalyst-free poly- condensation method, see Japanese Patent Unexamined
  • a polymer having free carboxyl groups at unspecified position can be produced by known production methods (e.g., see W094/15587 Publication) .
  • the lactic acid-glycolic acid polymer with a free carboxyl group at one end by chemical treatment after ring-opening polymerization is commercially available from Boehringer Ingelheim KG, for example.
  • pamoic acid or a salt thereof may be a commercially available pamoic acid or a salt thereof.
  • salts are alkaline metal salts (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salts (e.g. calcium salt, magnesium salt, etc.), transition metal (e.g. zinc, iron, copper etc.) and so on. Particularly, alkaline metal salts such as sodium salt are preferred.
  • alkaline metal salts such as sodium salt are preferred.
  • Examples of the solvents used for dissolution of the pamoic acid or a salt thereof and dissolution of the physiologically active peptide are water, alcohols (e.g. methanol, ethanol, etc.), pyridine, dimethylacetamide, acetic acid and so on.
  • alcohols such as methanol and so on.
  • organic solvents used for dissolution of the physiologically active peptide, pamoic acids or a salt and biodegradable polymer include halogenated hydrocarbons (e.g., dichloromethane, chloroform, dichloroethane, trichloroethane, carbon tetrachloride, etc.), ethers (e.g., ethyl ether, isopropyl ether, etc.), fatty acid esters (e.g., ethylacetate, butylacetate) , aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.) and alcohols (e.g. methanol, ethanol, etc.) with preference given to halogenated hydrocarbons, particularly dichloromethane .
  • halogenated hydrocarbons e.g., dichloromethane, chloroform, dichloroethane, trichloroethane, carbon tetrachloride, etc
  • the production method of the present invention is characterized in producing a sustained-release microsphere comprising (i) an about 0.01 to about 10 m particle size of a fine pamoic acid salt of the physiologically active peptide or (ii) a complex or salt formed by the physiologically active peptide, pamoic acid or a salt thereof and biodegradable polymer, wherein the fine pamoic acid salt and the complex or salt are formed by emulsification of a physiologically active peptide and a pamoic acid or a salt thereof with a biodegradable polymer, without preforming a pamoic acid salt of the physiologically active peptide in the absence of a biodegradable polymer as conducted in the past methods.
  • the mixing method of the physiologically active peptide, biodegradable polymer and pamoic acid or a salt thereof is not limited, so long as the pamoic acid salt is not formed in the absence of the biodegradable polymer .
  • the present invention specifically provides:
  • a method comprising emulsification of a solution of a physiologically active peptide or a salt thereof wherein the salt is not a pamoic acid salt and a solution of a pamoic acid or an alkaline metal salt thereof in a solution of a biodegradable polymer with an organic solvent, and removing the solvent;
  • a method comprising dissolving a physiologically active peptide or a salt thereof wherein the salt is not a pamoic acid salt, a pamoic acid or an alkaline metal salt thereof and a biodegradable polymer in an organic solvent, and removing the solvent;
  • a method comprising emulsification of a solution of a physiologically active peptide or a salt thereof wherein the salt is not a pamoic acid salt and a biodegradable polymer with an organic solvent and a solution of a pamoic acid or an alkaline metal salt thereof, and removing the solvent; and
  • a method comprising emulsification of solution of a biodegradable polymer and pamoic acid or an alkaline metal salt thereof with an organic solvent and a solution of a physiologically active peptide or a salt thereof wherein the salt is not a pamoic acid salt, and removing the solvent.
  • a concentration of the physiologically active peptide in the solution mixture is usually about 1 to about 25 wt%, preferably about 2 to about 20 wt% of the solution mixture.
  • a concentration of the biodegradable polymer in the solution mixture is usually about 1 to about 25 wt%, preferably about 2 to about 20 wt% of the solution mixture.
  • a concentration of the pamoic acid or a salt thereof in the solution mixture is usually about 0.05 to about 5 wt%, preferably about 0.2 to about 4 wt% of the solution mixture.
  • An amount of the solution of the pamoic acid or a salt thereof is usually about 2 to about 90 (v/v) % to the solution of the physiologically active peptide and the biodegradable polymer with an organic solvent.
  • in-water drying method for removing the solvent, in-water drying method, phase separation method and spray drying method are used.
  • the production method of the present invention is described specifically for each organic solvent removal method.
  • organic solvent examples include halogenated hydrocarbons (e.g., dichloromethane, chloroform, dichloroethane, trichloroethane, carbon tetrachloride), ethers (e.g., ethyl ether, isopropyl ether), fatty acid esters (e.g., ethyl acetate, butyl acetate) and aromatic hydrocarbons (e.g., benzene, toluene, xylene). These solvents may be used in combination.
  • the organic solvent used is preferably a halogenated hydrocarbon, more preferably dichloromethane.
  • physiologically active peptide when a sufficient amount of physiologically active peptide is soluble in a solvent (e.g., water, alcohols (e.g., ethanol, methanol), acetonitrile, acetic acid) in a volume within 60% of the entire volume of the solution of the biodegradable polymer, a solution of the physiologically active peptide may be added to the solution of the biodegradable polymer to yield a solution of both, or the physiologically active peptide solution is emulsified in the solution of the biodegradable polymer to yield an o/o or w/o emulsion. In these procedures, it is undesirable to precipitate the physiologically active peptide.
  • a solvent e.g., water, alcohols (e.g., ethanol, methanol), acetonitrile, acetic acid) in a volume within 60% of the entire volume of the solution of the biodegradable polymer
  • a solution of the physiologically active peptide may be added to
  • the concentration of the biodegradable polymer used here in the solution varies, depending on the molecular weight of biodegradable polymer used, the kind of organic solvent, etc., it is normally chosen over the range from about 0.5 to about 70% (w/w), preferably about 1 to about 60% (w/w), and most preferably about 2 to about 50% (w/w), when dichloromethane, for example, is used as the organic solvent.
  • the physiologically active peptide is normally added at about 30 mg to about 500 mg, preferably about 40 mg to about 400 mg, per ml of the above-described organic solvent in the biodegradable polymer solution.
  • a solution of a pamoic acid or a pamoate e.g., alkaline metal salts (sodium salt, potassium salt etc.), alkaline earth metal salts (e.g., calcium salt, magnesium salt) or salts with transition metals (e.g., zinc, iron, copper) (the solvent exemplified by water, alcohols (e.g., methanol, ethanol), pyridine, and dimethylacetamide) is added under emulsification by a known method such as the use of a homogenizer or ultrasonication.
  • alkaline metal salts sodium salt, potassium salt etc.
  • alkaline earth metal salts e.g., calcium salt, magnesium salt
  • transition metals e.g., zinc, iron, copper
  • the physiologically active peptide or a salt thereof and the pamoic acid or a salt thereof, and furthermore the pamoic acid salt of the physiologically active peptide are completely soluble in an organic solvent (e.g., alcohols (methanol, ethanol etc.))
  • this organic solvent solution is added to the organic solvent solution of the biodegradable polymer under emulsification by a known method such as the use of a homogenizer or ultrasonication.
  • the pamoic acid or pamoate concentration in the solution in the above-described two addition methods is not subject to limitation, as long as it does not exceed the saturation concentration, it is preferably the saturation concentration
  • the ratio by volume of the pamoic acid or pamoate solution to the biodegradable polymer solution is preferably about 2 to about 90%, more preferably about 5 to about 70%, and most preferably about 10 to about 50%.
  • the thus-obtained solution of the biodegradable polymer containing the physiologically active peptide and pamoic acid (oil phase) is added to the second water phase to form an o (oil phase)/w (water phase) emulsion, after which the solvent in the oil phase is evaporated to yield microspheres.
  • the volume of the water phase is normally chosen over the range from about 1 to about 10,000 times, preferably from about 2 to about 5,000 times, and most preferably from about 5 to about 2,000 times, that of the oil phase.
  • An emulsifier may be added to the above-described external water phase.
  • the emulsifier may be any one, as long as it is capable of forming a stable o/w emulsion.
  • Such emulsifiers include, for example, anionic surfactants (e.g., sodium oleate, sodium stearate, sodium lauryl sulfate), nonionic surfactants (e.g., polyoxyethylene sorbitan fatty acid esters (Tween 80, Tween 60, Atlas Powder Company), polyoxyethylene castor oil derivatives (e.g., HCO-60, HCO-50, Nikko Chemicals)), polyvinyl pyrrolidone, polyvinyl alcohol, carboxymethyl cellulose, lecithin, gelatin and hyaluronic acid. These emulsifiers may be used singly or in combination.
  • the emulsifier is preferably used at concentrations within the range from about 0.01% to about 10% (w/w),
  • An osmolarity regulator may be added to the above- described external water phase.
  • the osmolarity regulator may be any one, as long as it provides an osmolarity when prepared as an aqueous solution.
  • Examples of the osmolarity regulators are polyhydric alcohols, monohydric alcohols, monosaccharides, disaccharides, oligosaccharides or derivatives thereof.
  • Such polyhydric alcohols include, for example, dihydric alcohols such as glycerol, pentahydric alcohols such as arabitol, xylitol and adonitol, and hexahydric alcohols such as annitol, sorbitol and dulcitol. Of these alcohols, hexahydric alcohols are preferred, with greater preference given to mannitol.
  • Such monohydric alcohols include, for example, methanol, ethanol and isopropyl alcohol, with preference given to ethanol.
  • Such monosaccharides include, for example, pentoses such as arabinose, xylose, ribose and 2-deoxyribose, and hexoses such as glucose, fructose, galactose, mannose, sorbose, rhamnose and fucose, with preference given to hexoses.
  • Such oligosaccharides include, for example, trisaccharides such as maltotriose and raffinose, and tetrasaccharides such as stachyose, with preference given to trisaccharides.
  • Derivatives of such monosaccharides, disaccharides and oligosaccharides include, for example, glucosamine, galactosamine, glucuronic acid and galacturonic acid.
  • osmolarity regulators may be used singly or in combination.
  • osmolarity regulators are used at concentrations such that the osmolarity of the external water phase is about 1/50 to about 5 times, preferably about 1/25 to about 3 times, that of physiological saline.
  • Organic solvent removal can be achieved by known methods, including the method in which the organic solvent is evaporated under normal or gradually reduced pressure during stirring using a propeller stirrer, magnetic stirrer or the like, and the method in which the organic solvent is evaporated, while the degree of vacuum is adjusted.
  • microspheres also referred to as microcapsules
  • the thus-obtained microspheres are collected by centrifugation or filtration, after they are repeatedly washed with several additions of distilled water to remove the physiologically active peptide, pamoic acid, drug support, emulsifier etc. adhering to the microsphere surface, again dispersed in distilled water etc. and freeze-dried.
  • an anticoagulant may be added.
  • the anticoagulant is exemplified by water-soluble saccharides such as mannitol, lactose, glucose and starches (e.g., corn starch), and proteins such as glycine, fibrin and collagen.
  • the anticoagulant is preferably mannitol.
  • the microspheres may be heated under reduced pressure under conditions that do not cause their mutual fusion to remove the water and organic solvent therefrom.
  • the microspheres be heated at a temperature slightly higher than the midpoint of glass transition temperature of the biodegradable polymer, as obtained using a differential scanning calorimeter when the temperature is elevated at a rate of 10 to 20°C per minute. More preferably, the microspheres are heated within the temperature range from the midpoint of glass transition temperature of the biodegradable polymer to a temperature higher by about 30°C than the glass transition temperature.
  • the microspheres are heated within the temperature range from the midpoint of glass transition temperature to a temperature higher by 20°C than the glass transition temperature, preferably within the temperature range from the midpoint of glass transition temperature to a temperature higher by 10°C than the glass transition temperature.
  • heating time varies, depending on the amount of microspheres and other factors, it is generally preferable that heating time be about 12 to about 168 hours, more preferably about 48 to 120 hours after the microspheres reach a given temperature. Heating time is most preferably about 48 hours to about 96 hours.
  • Any heating method can be used, as long as microspheres are uniformly heated.
  • Preferable thermal drying methods include, for example, the method in which thermal drying is conducted in a thermostated chamber, fluidized bed chamber, mobile phase or kiln, and the method using microwaves for thermal drying. Of these methods, the method in which thermal drying is conducted in a thermostated chamber is preferred.
  • the phase separation method For producing microspheres by the phase separation method, a coacervating agent is gradually added to the oil phase described in the above (I) under stirring, to precipitate and solidify the biodegradable polymer.
  • the volume of the coacervating agent is about 0.01 to about 1,000 times, preferably about 0.05 to about 500 times, more preferably about 0.1 to about 200 times to the volume of the oil phase.
  • Any coacervating agent can be used, as long as it is a polymeric, mineral oil or vegetable oil compound miscible with the solvent for the biodegradable polymer and that does not dissolve the biodegradable polymer.
  • Such coacervating agents include silicon oil, sesame oil, soybean oil, corn oil, cotton seed oil, coconut oil, linseed oil, mineral oil, n-hexane and n-heptane. These may be used in combination of two or more kinds.
  • microspheres are filtered to separate them, after which they are repeatedly washed with hexane, heptane etc. and heated to remove the coacervating agent. If necessary, in the same manner as with the above- described in-water drying method, miocrospheres are washed with distilled water several times repeatedly to remove the free drug, drug-retaining substance etc. adhering to the microsphere surface.
  • spray drying method For producing microspheres by this method, the oil phase described in in-water drying method (I) above is sprayed via a nozzle into the drying chamber of a spray drier to volatilize the organic solvent in the fine droplets in a very short time, to yield microsphere.
  • the nozzle is exemplified by the double-fluid nozzle, pressure nozzle and rotary disc nozzle.
  • the microspheres may be then freeze-dried and thermally dried as necessary after being washed in the same manner as that described in in- water drying method (I).
  • the oil phase described in in-water drying method (I) for microsphere production may be dried by evaporating the organic solvent and water, while the degree of vacuum is adjusted, followed by milling with a jet mill or the like to yield a fine powder.
  • the milled fine powder may be then freeze-dried and thermally dried after being washed in the same manner as that described in in-water drying method (I) for microsphere production.
  • the microspheres or fine powder can be orally or non- orally administered as such or in the form of various dosage forms prepared using them as a starting material. Specifically, they can be administered as muscular, subcutaneous, visceral and other injectable preparations or implant preparations, nasal, rectal, uterine and other transdermal preparations, oral preparations (e.g., solid preparations such as capsules (e.g., hard capsules, soft capsules), granules and powders; liquids such as syrups, emulsions and suspensions) etc.
  • oral preparations e.g., solid preparations such as capsules (e.g., hard capsules, soft capsules), granules and powders; liquids such as syrups, emulsions and suspensions
  • microspheres or a fine powder can be prepared as injectable formulations by suspending in water with a dispersing agent (e.g, surfactants such as Tween 80 and HCO-60, polysaccharides such as carboxymethyl cellulose and sodium alginate), a preservative (e.g., methyl paraben, propyl paraben), an isotonizing agent (e.g., sodium chloride, mannitol, sorbitol, glucose, proline) etc. to yield an aqueous suspension, or by dispersing in a vegetable oil such as sesame oil or corn oil to yield an oily suspension, whereby a practically useful sustained- release injectable preparation is obtained.
  • a dispersing agent e.g, surfactants such as Tween 80 and HCO-60, polysaccharides such as carboxymethyl cellulose and sodium alginate
  • a preservative e.g., methyl paraben, propyl paraben
  • an isotonizing agent
  • the mean particle diameter is chosen over the range from about 0.1 to about 300 ⁇ m, as long as the requirements concerning the degree of dispersion and needle passage are met.
  • the mean particle diameter is about 1 to about 150 ⁇ m, more preferably about 2 to about 100 ⁇ .
  • microspheres or fine powder can be prepared as a sterile preparation by such methods as the method in which the entire production process is aseptic, the method using gamma rays for sterilization, and the method in which a preservative is added, which methods are not to be construed as limitative.
  • microsphere is any microparticle containing a physiologically active peptide and a biodegradable polymer.
  • the microsphere is preferably nearly spherical.
  • Such microparticles include, for example, microcapsules containing one drug core in each particle, a multiple-core microcapsule containing a large number of drug cores in each particle, and microparticles wherein a drug in the molecular form is dissolved or dispersed as a solid solution in a matrix.
  • the sustained-release microsphere of the present invention can be produced by the above-described production method of the present invention.
  • a physiologically active peptide having basic groups capable of forming salts with a pamoic acid particularly, a physiologically active peptide having the basic group
  • sustained-release microspheres comprising an about 0.01 to about 10 m particle size of fine pamoic acid salt of the physiologically active peptide and a biodegradable polymer
  • a physiologically active peptide is incorporated in microspheres at higher efficiencies than in the conventional microsphere production method, wherein a pamoic acid salt of a physiologically active peptide is formed in advance, then mixed with a biodegradable polymer to yield microspheres comprising the pamoic acid salt of the physiologically active peptide, to enable the production of microspheres containing a physiologically active peptide at high contents.
  • sustained-release microspheres comprising a similarly fine complex or salt formed with the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer, can be produced.
  • the salt comprising three components may be any one, as long as the physiologically active peptide is incorporated between the pamoic acid and biodegradable polymer via a reversible bond, and may be a salt belonging to ortho salts, acidic salts, basic salts, complex salts, chelate salts etc.
  • the salt can be formed by emulsification of the three components in a molecular dispersion or similar state (e.g., solution state).
  • the microsphere of the present invention which contains the salts of three components, is characterized in that the pamoic acid/physiologically active peptide molar ratio therein is evidently smaller than that in the microspheres obtained by the conventional method; this demonstrates that the salt is a new salt differing from the salt in the conventional microsphere, which produces using a pamoic acid salt of a physiologically active peptide formed in the absence of a biodegradable polymer.
  • the sustained-release microspheres of the present invention contain a physiologically active peptide at high contents; the physiologically active peptide release from the preparation depends on the dissociation and dissolution properties of the physiologically active peptide and/or a pamoic acid thereof, and the decomposition rate of the biodegradable polymer.
  • the present invention provides:
  • a sustained-release microsphere (A) which comprises an about 0.01 to about 10 ⁇ m particle size of a pamoic acid salt of a physiologically active peptide and a biodegradable polymer; and (2) A sustained-release microsphere (B) which comprises a complex or a salt formed by a physiologically active peptide, a pamoic acid or a salt thereof and a biodegradable polymer.
  • Each of the sustained-release microspheres (A) and (B) is a sustained-release microsphere which comprises not more than about 0.8 mol, preferably about 0.1 to about 0.8 mol, more preferably 0.2 to 0.8 mol, furthermore preferably about 0.3 to 0.7 mol to 1 mol of the physiologically active peptide.
  • the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer are same those as mentioned above.
  • physiologically active peptide are a physiologically active peptide having groups capable of forming salts with a pamoic acid, particularly a physiologically active peptide having one basic group.
  • physiologically active peptide are LH-RH agonist represented by the formula (lb), and particularly a compound C: 5-oxo-Pro-His-Trp-Ser-Tyr- DLeu-Leu-Arg-Pro-NH-C 2 Hs as shown in Example 11 as mentioned below, and so on.
  • the biodegradable polymer examples include a polylactic acid and a polymer of ⁇ -hydroxy carboxylic acids, and particularly a polylactic acid is prefered.
  • the weight-average molecular weight is, for example, 10,000 to 60,000, more preferably 15,000 to 50,000.
  • composition ratio of lactic acid/glycolic acid is preferably 100/0 to 40/60 (mol%).
  • Preferable weight- average molecular weight of the polymer is 5,000 to 80,000.
  • the particle size of the pamoic acid salt of the physiologically active peptide in the sustained-release microsphere (A) of the present invention is usually about 0.01 to about 10 ⁇ m, preferably about 0.02 to about 5 ⁇ m, more preferably about 0.02 to about 4 ⁇ m.
  • the pamoic acid is usually included at the ratio of not more than about 0.8 mol, preferably about 0.1 to about 0.8 mol, more preferably about 0.2 to 0.8 mol, furthermore preferably about 0.3 to 0.7 mol to 1 mol of the physiological active peptide.
  • the emulsification ratio of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer in the sustained- release microsphere (A) may vary depending on kind of the physiologically active peptide, desired pharmacological action, duration of action and other factors, a ratio of the physiologically active peptide is usually not less than 15 wt%, preferably about 15 to about 85 wt%, more preferably about 20 to about 80 wt%, furthermore preferably about 20 to about 50 wt% to the total microspheres.
  • a content of the peptide is preferably about 15 to about 30 wt%.
  • a ratio of the pamoic acid or a salt thereof in the sustained-release microsphere (A) is usually about 0.1 to about 25 wt%, preferably about 0.5 to about 15 wt%, more preferably about 1 to about 10 wt% to the microsphere.
  • a ratio of the pamoic acid salt of the physiologically active peptide in the sustained-release microsphere (A) is usually about 15 (or about 15.1) to about 95 wt%, preferably about 20 to about 90 wt% to the sustained- release microspheres.
  • a ratio of the biodegradable polymer is usually about 15 to 85 wt%, preferably about 30 to about 60 wt% to the sustained-release microspheres.
  • the physiologically active peptides usually form salts with a pamoic acid, a part of the physiologically active peptides may exist without forming the salts.
  • microsphere (B) of the present invention examples of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer are same those as mentioned above.
  • physiologically active peptide are a physiologically active peptide having not less than 2 basic groups capable of forming salts with a pamoic acid.
  • preferable examples of the physiologically active peptide are a LH-RH antagonist represented by the formula (la), and particularly a compound A as shown in Example 1 as mentioned below, and so on.
  • the biodegradable polymer are a polymer of ⁇ -hydroxy carboxylic acids, and particularly a lactic acid/glycolic acid polymer is prefered.
  • a composition ratio of lactic acid/glycolic acid is preferably 100/0 to 40/60 (mol%).
  • Preferable weight-average molecular weight of the polymer is 5,000 to 80,000.
  • the particle size of the pamoic acid salt of the physiologically active peptide in the sustained-release microsphere (B) of the present invention is usually about 0.01 to about 10 ⁇ m, preferably about 0.02 to about 5 ⁇ m, more preferably about 0.02 to about 4 ⁇ m.
  • the pamoic acid is usually included at the ratio of not more than about 0.8 mol, preferably about 0.1 to about 0.8 mol, more preferably about 0.2 to 0.8 mol, furthermore preferably about 0.3 to 0.7 mol to 1 mol of the physiological active peptide.
  • the emulsification ratio of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer in the sustained- release microsphere (B) may vary depending on kind of the physiologically active peptide, desired pharmacological action, duration of action and other factors, a ratio of the physiologically active peptide is usually not less than 15 wt%, preferably about 15 to about 85 wt%, more preferably about 20 to about 80 wt%, furthermore preferably about 30 to about 80 wt%, for still more preferably about 40 to about 80wt% to the microspheres as sum of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer.
  • a ratio of the pamoic acid or a salt thereof in the microsphere (B) is usually about 0.1 to about 25 wt%, preferably about 0.5 to about 15 wt%, more preferably about 1 to about 10 wt% to the microspheres as sum of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer.
  • a ratio of the biodegradable polymer in the microsphere (B) is usually about 15 to about 85 wt%, preferably about 30 to about 60 wt% to the microspheres as sum of the physiologically active peptide, the pamoic acid or a salt thereof and the biodegradable polymer.
  • the physiologically active peptides usually form salts with a pamoic acid or a salt thereof and a biodegradable polymer, a part of the physiologically active peptides may exist without forming the salts.
  • the particle size of the pamoic acid salt of the physiologically active peptide can be determined by observing an oil phase in the way of preparing or a cross section of the microsphere with an optical microscope, or by observing a cross section of the microsphere with an electron microscope.
  • the sustained-release microsphere of the present invention is of low toxicity and can be used safely to human or mammals (e.g., monkey, bovines, pigs, dogs, cats, mice, rats, rabbits, etc.) as various sustained-release preparations.
  • human or mammals e.g., monkey, bovines, pigs, dogs, cats, mice, rats, rabbits, etc.
  • the dose of the active ingredient of the microsphere preparation may be set at any level, as long as the active ingredient is effective.
  • the dose of the physiologically active peptides per administration can be chosen as appropriate over the range from about 0.001 mg to about 100 mg, preferably from about 0.01 mg to about 50 mg more preferably about 0.05 mg to about 10 mg per adult (weight 50 kg) in terms of the weight of microsphere.
  • the LH-RH antagonist represented by the general formula [la] above or the LH-RH agonist represented by the general formula [lb] can be used as the physiologically active peptide, it can be used as a treating or preventive agent for hormone-depending diseases such as prostatic cancer, prostatic hypertrophy, endometritis, hysteromyoma, dysmenorrhea, metrofibroma, precocious puberty, breast cancer, gallbladder cancer, cervical cancer, chronic lymphatic leukemia, chronic myelocytic leukemia, colorectal cancer, gastritis,
  • hormone-depending diseases such as prostatic cancer, prostatic hypertrophy, endometritis, hysteromyoma, dysmenorrhea, metrofibroma, precocious puberty, breast cancer, gallbladder cancer, cervical cancer, chronic lymphatic leukemia, chronic myelocytic leukemia, colorectal cancer, gastritis,
  • Hodgkin's disease malignant melanoma, metastases, multiple myeloma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, digestive ulcers, systemic fungal infections, small cell lung cancer, valvular disease of the heart, mastopathy, polycystic ovary, infertility, chronic anovulation, appropriately induced ovulation in women, acnes, amenorrhea (e.g., secondary amenorrhea), cystic diseases of the ovary and breast (including polycystic ovary), gynecologic cancers, ovarian hyperandrogenemia and hypertrichosis, AIDS due to T-cell production mediated by thymic blastogenesis, male contraception for treatment of and male sex criminals, as an agent for contraception and mitigation of symptoms of premenstrual syndrome (PMS), as a drug for in ⁇ itro fertilization (IVF), and for other purposes, especially as a
  • the dose of the physiologically active peptide may be set at any level, as long as it is pharmacologically effective.
  • the dose per administration of the drug can preferably be chosen as appropriate over the range from about 0.005 mg to about 10 mg/kg body weight per adult in the case of a 1-month sustained-release preparation. More preferably, it can be chosen as appropriate over the range from about 0.02 mg to about 5 mg/kg body weight.
  • the dose per administration of the microsphere in the sustained-release preparation can preferably be chosen as appropriate over the range from about 0.005 mg to 50 mg/kg body weight per adult. More preferably, it can be chosen as appropriate over the range from about 0.02 mg to 30 mg/kg body weight.
  • Dosing frequency can be chosen as appropriate, e.g., once every several weeks, once every month, or once every several months, depending on kind and content of active ingredient physiologically active peptide, dosage form, duration of physiologically active peptide release, target disease, subject animal species etc.
  • Example 1 A solution of 100 mg of pamoic acid in 2.7 ml of pyridine was added to a solution of 972 mg of N-(S)-2- tetrahydrofuroyl-Gly-D2Nal-D4ClPhe-D3Pal-Ser-NMeTyr- DLys(Nic)-Leu-Lys(Nisp)-Pro-DAlaNH 2 (herein after abbreviated to as Compound A) acetate (produced by TAP Company) and 1040 mg of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid (molar ratio %) 50/50; weight- average molecular weight, 6,150; number-average molecular weight, 2,400; number-average molecular weight based on terminal group titration, 2,300; produced by Wako Pure Chemical) in 3 ml of dichloromethane.
  • Compound A acetate
  • lactic acid-glycolic acid copolymer lactic
  • the mixture was emulsified using a small homogenizer for 60 seconds to yield S/O suspension (pamoic acid/Compound A (molar ratio), 0.5). After being cooled to 18°C, the suspension was poured into 400 ml of 0.1% aqueous solution of polyvinyl alcohol (EG-40, produced by Nippon Synthetic Chemical
  • microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered microspheres. Encapsulation efficiency of Compound A into the microspheres was 90.2%. Content of Compound A and molar ratio of pamoic acid/Compound A in the microspheres were 38.6% and 0.49, respectively.
  • Microspheres were obtained in similar manner to Example 1, except that lactic acid-glycolic acid copolymer was replaced by one (lactic acid/glycolic acid (molar ratio), 50/50; weight-average molecular weight, 10,100; number-average molecular weight, 3,720; number-average molecular weight based on terminal group titration, 3,500) and an amount of dichloromethane was 3.5 ml.
  • Pamoic acid/Compound A (molar ratio) was 0.5.
  • Encapsulation efficiency of Compound A into the microspheres was 91.8%.
  • Content of Compound A and pamoic acid/Compound A in the microspheres were 39.2% and 0.51, respectively.
  • Microspheres were obtained in a similar manner to Example 1, except that lactic acid-glycolic acid copolymer was replaced by one (lactic acid/glycolic acid (molar ratio), 50/50; weight-average molecular weight, 12,700; number-average molecular weight; 4,780; number-average molecular weight based on terminal group titration, 4,900) and amount of dichloromethane was 3.8 ml.
  • Added pamoic acid/Compound A (molar ratio) was 0.5.
  • Encapsulation efficiency of Compound A into the microspheres was 89.9%.
  • Content of Compound A and pamoic acid/Compound A in the microspheres were 38.4% and 0.53, respectively.
  • Example 4 Microspheres were obtained in a similar manner to
  • Example 3 except the amount of pamoic acid and pyridine in Example 1 were changed to 200 mg and 5 ml, respectively.
  • Added pamoic acid/Compound A (molar ratio) was 1.0.
  • Encapsulation ratio of Compound A into the microspheres was 94.1%.
  • Content of Compound A and pamoic acid/Compound A in the microspheres were 38.3% and 0.63, respectively.
  • Compound A acetate produced by TAP Company
  • 1040 mg of lactic acid-glycolic acid copolymer lactic acid/glycolic acid (molar %, 50/50); weight-average molecular weight, 12,700; number-average molecular weight, 4,780; number- average molecular weight based on terminal group titration, 4,900; produced by Wako Pure Chemical) in 4 ml of dichloromethane (pamoic acid/Compound A (molar ratio), 0.5).
  • the mixture was emulsified using a small homogenizer for 60 seconds to yield S/O suspension (or W/O emulsion).
  • the suspension After being cooled to 18°C, the suspension was poured into 400 ml of 0.1% aqueous solution of polyvinyl alcohol (EG- 40, produced by Nippon Synthetic Chemical Industry Co., Ltd.) containing 5% mannitol, which had been previously adjusted at 18°C.
  • the resultant mixture was prepared into S/O/W emulsion with the use of a turbin type homomixer at 7,000 rpm.
  • the emulsion was stirred at room temperature for 3 hours to volatilize off the dichloromethane and solidify the oil phase, which was then collected by centrifugation with a centrifuge (05PR-22, Hitachi Ltd.) at 2,000 rpm.
  • the resulting precipitate was again dispersed in distilled water, followed by centrifugation and removal of the separated free drug, etc.. After the collection microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered microspheres. Encapsulation efficiency of Compound A into the microspheres was 89.8%. Content of Compound A and pamoic acid/Compound A (molar ratio) in the microspheres were 38.4% and 0.56, respectively.
  • Example 6 Microspheres were obtained in a similar manner to Example 5, except that the lactic acid-glycolic acid copolymer was replaced by one (lactic acid/glycolic acid (molar ratio %, 65/35); weight-average molecular weight, 12,500; number-average molecular weight, 4,170 and number- average molecular weight based on terminal group titration, 4,000) and the amount of dichloromethane was changed to 4.5 ml. Added pamoic acid/Compound A (molar ratio) was 0.5. Encapsulation ratio of Compound A into the microspheres was 89.6%. Content of Compound A and pamoic acid/Compound A (molar ratio) in the microspheres were 38.3% and 0.57, respectively.
  • lactic acid/glycolic acid molar ratio %, 65/35
  • weight-average molecular weight 12,500
  • number-average molecular weight 4,170 and number- average molecular weight based on terminal group titration, 4,000
  • the resulting mixture was emulsified using a small homogenizer for 60 seconds to yield S/O suspension (or W/O emulsion). After being cooled to 18°C, the resulting suspension was poured into 1600 ml of 0.1% aqueous solution of polyvinylalcohol (EG-40, produced by Nippon Synthetic Chemical Industry Co., Ltd.) containing 5% mannitol, which had been previsously adjusted at 18°C. The resulting mixture was prepared into S/O/W emulsion with the use of a turbine type homomixer at 7,000 rpm.
  • EG-40 polyvinylalcohol
  • the emulsion was stirred at room temperature for 3 hours to volatilize off the dichloromethane and to solidify the oil phase, which was then collected by centrifugation with a centrifuge (05PR-22, Hitachi Ltd.) at 2,000 rpm. The resulting precipitate was again dispersed in distilled water, followed by centrifugation and removal of the separated free drug, etc.. After the collection microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered microspheres. The resulting microspheres were dried at 40°C for 96 hours under reduced pressure in an oven. Encapsulation efficiency of Compound A into the obtained microspheres (average diameter 22 m)was 93.8%. Content of Compound A and pamoic acid/Compound A (molar ratio) in the microspheres were 41.0% and 0.52, respectively.
  • the resulting mixture was emulsified using a small homogenizer for 60 seconds to yield S/O suspension (or W/O emulsion). After being cooled to 18°C, the suspension was poured into 800 ml of 0.1% aqueous solution of polyvinyl alcohol (EG-40, produced by Nippon Synthetic Chemical Industry Co., Ltd.) containing 5% mannitol, which had been previously adjusted at 18°C. The resulting mixture was prepared into S/O/W emulsion with the use of a turbine-type homomixer at 7,000 rpm.
  • EG-40 polyvinyl alcohol
  • the resulting emulsion was stirred at room temperature for 3 hours to volatilize off the dichloromethane and to solidify the oil phase, which was then collected by centrifugation with a centrifuge (05PR- 22, Hitachi Ltd.) at 2,000 rpm.
  • the resulting precipitate was again dispersed in distilled water, followed by centrifugation and removal of the separated free drug, etc..
  • After the collection microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered microspheres.
  • Encapsulation efficiency of Compound B into the microspheres was 98.9%.
  • Content of Compound B and molar ratio of pamoic acid/Compound B in the microspheres were 43.6% and 0.52, respectively.
  • a solution of 0.47 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid (molar ratio %), 50/50); weight-average molecular weight, 18,700; number- average molecular weight, 6,180; number-average molecular weight based on terminal group titration, 6,000; produced by Wako Pure Chemical) in 15 ml of dichloromethane was added to a solution of 1,012 g of Compound A acetate (produced by TAP Company) and 0.112 g of disodium pamoic acid in 6 ml of methanol to prepare a homogeneous solution. From the solution the organic solvent was volatilized off by a rotary evaporator.
  • a solution of 0.056 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid (molar ratio), 50/50; weight-average molecular weight, 12,700; number-average molecular weight, 4,780; number-average molecular weight based on terminal group titration, 4,900; produced by Wako Pure Chemical) in 6 ml of dichloromethane, was added to a solution of 0.506 g of Compound A acetate (produced by TAP Company) and 0.056 g of disodium pamoic acid in 3 ml of methanol to prepare a homogeneous solution. From the solution the organic solvent was volatilized off by a rotary evaporator.
  • the pamoic acid salt of Compound A of Comparative Example 1 was ground. Using the salt of pamoic acid having an average particle size of 14 ⁇ m, microspheres were prepared by the following procedure.
  • Pamoic acid salt of Compound A (pamoic acid/Compound A (molar ratio)1.08) was added to a solution of 1.04 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid (molar ratio), 50/50; average-weight molecular weight. 12,700; number-average molecular weight, 4,780 and number- average molecular weight based on terminal group titration, 4,500) in 4 ml of dichloromethane. The resultant mixture was emulsified with a small homogenizer to prepare S/O suspension. Using the suspension, microspheres were prepared in a similar manner to Example 1.
  • Encapsulation efficiency of Compound A into the microspheres was as low as 15%. Content of Compound A was 6.1%. From the fact that pamoic acid/Compound A (mole ratio) in the microspheres was the same as 1.12 of before encapsulation. Compound A was encapsuled as the salt of pamoic acid per se and is not considered to form a salt of copolymer of lactic acid-glycolic acid.
  • Microspheres were prepared in a similar manner to Example 3 except that pamoic acid and pyridine in Example 1 were not used. Encapsulation ratio of Compound A into the microspheres was 41.1%. Content of Compound A in the microspheres was 18.5%.
  • the suspension After being cooled to 18°C, the suspension was poured into 400 ml of 0.1 % aqueous solution of polyvinyl alcohol (EG-40, Nippon Synthetic Chemical Industry Co., Ltd.) containing 5% of mannitol. Using a turbine-type homomixer, the mixture was prepared into S/O/W emulsion at 7,000 rpm. The resulting emulsion was stirred at room temperature for 3 hours to volatilize off dichloromethane and to solidify the oil phase, which was collected by centrifuge (5PR-22, Hitachi Ltd.) at 2,000 rpm. The resulting microspheres were dispersed in distilled water and further centrfiuged, followed by removing the separated drug, etc..
  • polyvinyl alcohol EG-40, Nippon Synthetic Chemical Industry Co., Ltd.
  • the collected microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered microspheres. Encapsulation efficiency of Compound C into the microspheres was 86.4%. Content of Compound C and pamoic acid/Compound A (mole ratio) in the microspheres were 18.2% and 0.50, respectively.
  • Example 12 Microspheres were prepared in a similar manner to
  • Example 11 except that the polylactic acid was replaced by 1,500 mg of polylactic acid (weight-average molecular weight, 17,000; number-average molecular weight, 5,000; number-average molecular weight based on terminal group titration, 5,500; produced by Wako Pure Chemical), the amount of dichloromethane was changed to 8 ml and the methanol solution of disodium pamoic acid was replaced by 1.1 ml of a distilled water solution. Encapsulation efficiency of Compound C into the microspheres was 92.8%. Content of Compound C and pamoic acid/Compound C (mole ratio) in the microspheres were 21.9% and 0.78, respectively.
  • Example 13 An aqueous solution of 1,000 mg of Compound C dissolved in 0.9 ml of distilled water was added to a solution of 3,600 mg of lactic acid (weight-average molecular weight, 24.300; number-average molecular weight, 7.790; number-average molecular weight based on terminal group titration, 8,000; produced by Wako Pure Chemical) in 8 ml of dichloromethane. The resulting mixture was emulsified using a small homogenizer for 60 seconds to yield W/O emulsion, followed by addition of a solution of 204 ml of disodium pamoic acid in 2 ml of methanol.
  • the resulting mixture was again emulsified using a small 0 homogenizer for 60 seconds to produce an almost clear but slightly opaque yellow solution. After being cooled to 18°C, the resulting yellow solution was poured into 800 ml of an aqueous solution of 0.1% polyvinyl alcohol (EG-40, produced by Nippon Synthetic Chemical) containing 5% 5 mannitol. The resulting mixture was prepared into O/W emulsion by a turbine-type homomixer at 7,000 rpm. The resulting emulsion was stirred at room temperature for 3 hours to volatilize off the dichloromethane and to solidify the oil phase, which was collected by centrifuge (05PR-22, o Hitachi Ltd.) at 2,000 rpm.
  • EG-40 polyvinyl alcohol
  • the resulting microspheres were again dispersed in distilled water and centrifuged, followed by removing the separated drug, etc..
  • the collected microspheres were again dispersed in a small amount of distilled water and lyophilized to yield powdered 5 microspheres.
  • Encapsulation efficiency of Compound C into the microspheres was 100.0%.
  • Content of Compound C and pamoic acid/Compound C (mole ratio) in the microspheres were 20.9% and 0.57, respectively. 0
  • Microspheres were prepared in a similar manner to Example 13 using yellow solution as prepared in Example 13, except that the polylactic acid was replaced by one 5 (weight-average molecular weight, 40,000; number-average molecular weight, 26,700; produced by Taki Chemical) and the amount of dichloromethane was changed to 9 ml. Encapsulation efficiency of Compound C into the microspheres was 100.3%. Content of Compound C and pamoic acid/Compound C (mole ratio) in the microspheres were 21.0% and 0.56, respectively.
  • Microspheres were prepared in a similar manner to Example 13 except that amounts of the polylactic acid, dichloromethane, disodium pamoic acid and methanol were changed to 5000 mg, 10 ml, 130 mg and 1.3 ml, respectively (the oil phase was not a solution observed in Example 13 but a W/O emulsion) .
  • the resulting microspheres were further dried at 55°C for 120 hours under reduced pressure in an oven. Encapsulation efficiency of Compound C into the microspheres was 100.0%. Content of Compound C and pamoic acid/Compound C (mole ratio) in the microspheres were 16.4% and 0.39, respectively.
  • Microspheres were prepared in a similar manner to Example 11, except that the methanol solution of disodium pamoic acid was not added. Content of Compound C in the obtained microspheres was 7.7%.
  • microspheres were prepared using oil phase, wherein pamoic acid salt of Compound C was dispersed, by in-water drying method as a similar manner to Example 11, except that neither the aqueous solution of Compound C nor methanol solution of disodium pamoic aicd was added. Content of Compound C in the obtained microspheres was 7.4%.
  • Microspheres were prepared in a similar manner to Example 12, except that an aqueous solution of disodium pamoic acid in distilled water was not added. Content of Compound C in the obtained microspheres was 11.3%.
  • the microsphere of the present invention contains a large amount of the physiologically active peptide and can regulate a release rate of the physiologically peptide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à un procédé de production d'une microsphère à libération prolongée qui consiste en l'émulsification d'un peptide physiologiquement actif et d'un acide pamoïque par un polymère biodégradable. L'invention se rapporte également à une microsphère à libération prolongée comportant des particules de taille comprise approximativement entre 0,01 et 10 νm, d'un sel d'acide pamoïque d'un peptide physiologiquement actif et un polymère biodégradable. Elle se rapporte également à une microsphère à libération prolongée comportant un complexe ou un sel formé par un peptide physiologiquement actif, un acide pamoïque ou un sel de cet acide et un polymère biodégradable, et enfin à une préparation à libération prolongée contenant ladite microsphère. Cette microsphère contient une grande quantité de peptide physiologiquement actif et est susceptible de réguler la vitesse de libération du peptide physiologiquement actif.
PCT/JP1998/000339 1997-01-29 1998-01-28 Microspheres a liberation prolongee, leur production et utilisation WO1998032423A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56783/98A AU5678398A (en) 1997-01-29 1998-01-28 Sustained-release microspheres, their production and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/15203 1997-01-29
JP1520397 1997-01-29

Publications (1)

Publication Number Publication Date
WO1998032423A1 true WO1998032423A1 (fr) 1998-07-30

Family

ID=11882320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/000339 WO1998032423A1 (fr) 1997-01-29 1998-01-28 Microspheres a liberation prolongee, leur production et utilisation

Country Status (2)

Country Link
AU (1) AU5678398A (fr)
WO (1) WO1998032423A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020034A1 (fr) * 1998-10-08 2000-04-13 Takeda Chemical Industries, Ltd. Agents destines a retarder le passage d'un cancer hormono-dependant a un cancer hormono-independant
WO2000047234A1 (fr) * 1999-02-08 2000-08-17 Zentaris Ag Sels d'agents pharmaceutiques a liberation prolongee et leur production
WO2001005380A1 (fr) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
WO2001087265A2 (fr) * 2000-05-18 2001-11-22 Zentaris Ag Forme d'administration pharmaceutique pour des peptides, son procede de production et son utilisation
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
WO2002087616A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
WO2003072059A2 (fr) * 2002-02-27 2003-09-04 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
US6740634B1 (en) 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
WO2005046645A1 (fr) * 2003-11-14 2005-05-26 Novartis Ag Composition pharmaceutique
EP1651136A2 (fr) * 2003-07-15 2006-05-03 PR Pharmaceuticals Procede de preparation de compositions a liberation controlee
EP1656115A2 (fr) * 2003-07-23 2006-05-17 PR Pharmaceuticals Compositions a liberation controlee
EP1660039A2 (fr) * 2003-07-18 2006-05-31 Oakwood Laboratories L.L.C. Prevention de reduction de poids moleculaire du polymere, de formation d'impuretes et de gelification dans des compositions polymeres
WO2008142153A1 (fr) * 2007-05-24 2008-11-27 Novartis Ag Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
US8088726B2 (en) 2002-06-25 2012-01-03 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
WO2012037289A2 (fr) 2010-09-14 2012-03-22 The Regents Of The University Of California L'acide pamoïque bloque la signalisation de l'éthylène
CN1878541B (zh) * 2003-11-14 2013-01-16 诺瓦提斯公司 包含生长激素释放抑制因子类似物的微粒
US8815801B2 (en) 2001-06-29 2014-08-26 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
US8916196B2 (en) 2003-04-10 2014-12-23 Evonik Corporation Method for the production of emulsion-based microparticles
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
WO2016020901A1 (fr) 2014-08-07 2016-02-11 Acerta Pharma B.V. Procédés de traitement de cancers, maladies immunitaires et auto-immunes, et maladies inflammatoires basés sur l'occupation de btk et le taux de resynthèse de btk
EP1466596B1 (fr) * 2001-12-26 2016-08-31 Takeda Pharmaceutical Company Limited Microsphere et son procédé de production
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3822459A1 (de) * 1987-09-21 1989-03-30 Bpd Biopharm Dev Ltd Wasserunloesliche polypeptide
GB2234169A (en) * 1989-07-28 1991-01-30 Debiopharm Sa A method for preparing a sustained release pharmaceutical peptide composition
GB2257909A (en) * 1991-07-22 1993-01-27 Debio Rech Pharma Sa Preparation of controlled release peptide compositions
EP0626170A2 (fr) * 1993-05-10 1994-11-30 Sandoz Ltd. Stabilisation de composés pharmacoligiquement actifs dans des compositions à libération contrôlée
WO1995015767A1 (fr) * 1993-12-09 1995-06-15 Asta Medica Aktiengesellschaft Suspensions pour injection a action prolongee et procede de preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3822459A1 (de) * 1987-09-21 1989-03-30 Bpd Biopharm Dev Ltd Wasserunloesliche polypeptide
GB2234169A (en) * 1989-07-28 1991-01-30 Debiopharm Sa A method for preparing a sustained release pharmaceutical peptide composition
GB2257909A (en) * 1991-07-22 1993-01-27 Debio Rech Pharma Sa Preparation of controlled release peptide compositions
EP0626170A2 (fr) * 1993-05-10 1994-11-30 Sandoz Ltd. Stabilisation de composés pharmacoligiquement actifs dans des compositions à libération contrôlée
WO1995015767A1 (fr) * 1993-12-09 1995-06-15 Asta Medica Aktiengesellschaft Suspensions pour injection a action prolongee et procede de preparation

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740634B1 (en) 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
US7388032B2 (en) 1998-01-16 2008-06-17 Takeda Pharmaceutical Company Limited Sustained release compositions, process for producing the same and utilization thereof
WO2000020034A1 (fr) * 1998-10-08 2000-04-13 Takeda Chemical Industries, Ltd. Agents destines a retarder le passage d'un cancer hormono-dependant a un cancer hormono-independant
AU768882B2 (en) * 1999-02-08 2004-01-08 Zentaris Gmbh Sustained release salts of pharmaceutically active peptides and their production
WO2000047234A1 (fr) * 1999-02-08 2000-08-17 Zentaris Ag Sels d'agents pharmaceutiques a liberation prolongee et leur production
US7265157B1 (en) 1999-07-15 2007-09-04 Takeda Pharmaceutical Company Limited Sustained release compositions, process for producing the same and use thereof
WO2001005380A1 (fr) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
CN100342908C (zh) * 2000-05-18 2007-10-17 赞塔里斯有限公司 施用肽的药物剂型,其制备方法和应用
WO2001087265A3 (fr) * 2000-05-18 2002-04-18 Zentaris Ag Forme d'administration pharmaceutique pour des peptides, son procede de production et son utilisation
CZ303981B6 (cs) * 2000-05-18 2013-07-31 Zentaris Gmbh Farmaceutická aplikacní forma vhodná k parenterálnímu podávání peptidových antagonistu a zpusob její výroby a pouzití
US7718599B2 (en) 2000-05-18 2010-05-18 Aeterna Zentaris Gmbh Pharmaceutical administration form for peptides, process for its preparation, and use
WO2001087265A2 (fr) * 2000-05-18 2001-11-22 Zentaris Ag Forme d'administration pharmaceutique pour des peptides, son procede de production et son utilisation
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
WO2002087616A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
US8815801B2 (en) 2001-06-29 2014-08-26 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
EP1466596B1 (fr) * 2001-12-26 2016-08-31 Takeda Pharmaceutical Company Limited Microsphere et son procédé de production
WO2003072059A2 (fr) * 2002-02-27 2003-09-04 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
WO2003072059A3 (fr) * 2002-02-27 2003-12-31 Univ Wake Forest L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
US8034781B2 (en) 2002-02-27 2011-10-11 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US8088726B2 (en) 2002-06-25 2012-01-03 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US8916196B2 (en) 2003-04-10 2014-12-23 Evonik Corporation Method for the production of emulsion-based microparticles
US10272044B2 (en) 2003-04-10 2019-04-30 Evonik Corporation Method for the production of emulsion-based microparticles
US8871269B2 (en) 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
EP1651136A2 (fr) * 2003-07-15 2006-05-03 PR Pharmaceuticals Procede de preparation de compositions a liberation controlee
EP1651136A4 (fr) * 2003-07-15 2009-07-08 Pr Pharmaceuticals Inc Procede de preparation de compositions a liberation controlee
EP2462896A1 (fr) * 2003-07-15 2012-06-13 PR Pharmaceuticals Inc. Procédé de préparation de formules à libération contrôlée
EP1660039A4 (fr) * 2003-07-18 2009-08-12 Oakwood Lab L L C Prevention de reduction de poids moleculaire du polymere, de formation d'impuretes et de gelification dans des compositions polymeres
US9017715B2 (en) 2003-07-18 2015-04-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
EP2462923A3 (fr) * 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Prévention de la réduction du poids moléculaire du polymère, de la formation d'impuretés et de la gélification de compositions polymères
US8343513B2 (en) 2003-07-18 2013-01-01 Oakwood Laboratories, Llc Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
EP1660039A2 (fr) * 2003-07-18 2006-05-31 Oakwood Laboratories L.L.C. Prevention de reduction de poids moleculaire du polymere, de formation d'impuretes et de gelification dans des compositions polymeres
EP1656115A4 (fr) * 2003-07-23 2009-07-08 Pr Pharmaceuticals Compositions a liberation controlee
EP1656115A2 (fr) * 2003-07-23 2006-05-17 PR Pharmaceuticals Compositions a liberation controlee
EP2444069A1 (fr) * 2003-07-23 2012-04-25 PR Pharmaceuticals Inc. Compositions à libération contrôlée
US8900636B2 (en) 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
AU2004289055B2 (en) * 2003-11-14 2008-10-30 Recordati Ag Microparticles comprising somatostatin analogues
US8188037B2 (en) 2003-11-14 2012-05-29 Novartis Ag Microparticles comprising somatostatin analogues
WO2005046645A1 (fr) * 2003-11-14 2005-05-26 Novartis Ag Composition pharmaceutique
US7759308B2 (en) 2003-11-14 2010-07-20 Novartis Ag Microparticles comprising somatostatin analogues
AU2004289055C1 (en) * 2003-11-14 2009-05-21 Recordati Ag Microparticles comprising somatostatin analogues
CN1878541B (zh) * 2003-11-14 2013-01-16 诺瓦提斯公司 包含生长激素释放抑制因子类似物的微粒
US9713595B2 (en) 2006-12-18 2017-07-25 Takeda Pharmaceuticals Company Limited Sustained-release composition and method for producing the same
US9617303B2 (en) 2006-12-18 2017-04-11 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
EA018203B1 (ru) * 2007-05-24 2013-06-28 Новартис Аг Композиция пролонгированного высвобождения, содержащая памоат пасиреотида в микрочастицах с полимерной матрицей, способ получения микрочастиц и способ лечения
CN101677965B (zh) * 2007-05-24 2015-09-09 诺华股份有限公司 包含位于微粒中的生长抑素衍生物的延长释放组合物
EP3666263A1 (fr) * 2007-05-24 2020-06-17 Recordati AG Une composition à libération controlée qui contient une dérivé de somatostatine dans les microparticules
US9351923B2 (en) 2007-05-24 2016-05-31 Novartis Ag Extended-release composition comprising a somatostatin derivative in microparticles
WO2008142153A1 (fr) * 2007-05-24 2008-11-27 Novartis Ag Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
EP2615914A4 (fr) * 2010-09-14 2014-04-16 Univ California L'acide pamoïque bloque la signalisation de l'éthylène
EP2615914A2 (fr) * 2010-09-14 2013-07-24 The Regents of The University of California L'acide pamoïque bloque la signalisation de l'éthylène
US9877479B2 (en) 2010-09-14 2018-01-30 The Regents Of The University Of California Pamoic acid blocks ethelyne signaling
WO2012037289A2 (fr) 2010-09-14 2012-03-22 The Regents Of The University Of California L'acide pamoïque bloque la signalisation de l'éthylène
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
WO2017025814A1 (fr) 2014-08-07 2017-02-16 Acerta Pharma B.V. Méthodes de traitement de cancers, de maladies immunes et auto-immunes et de maladies inflammatoires fondées sur les taux d'occupation et de re-synthèse de btk
WO2016020901A1 (fr) 2014-08-07 2016-02-11 Acerta Pharma B.V. Procédés de traitement de cancers, maladies immunitaires et auto-immunes, et maladies inflammatoires basés sur l'occupation de btk et le taux de resynthèse de btk

Also Published As

Publication number Publication date
AU5678398A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
WO1998032423A1 (fr) Microspheres a liberation prolongee, leur production et utilisation
JP5931147B2 (ja) 徐放性組成物およびその製造法
EP0586238B1 (fr) Procédé de préparation de microcapsules à libération prolongée
US7388032B2 (en) Sustained release compositions, process for producing the same and utilization thereof
JP5622760B2 (ja) 乳酸重合体及びその製造方法
JP4819173B2 (ja) 徐放性組成物およびその製造法
US9713595B2 (en) Sustained-release composition and method for producing the same
AU2002311630A1 (en) Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
KR100994658B1 (ko) 신규 마이크로스피어 및 이들의 제조 방법
JPH10273447A (ja) 徐放性マイクロスフィア、その製造法および用途
JP3902518B2 (ja) 徐放性組成物用乳酸−グリコール酸重合体の製造法
JP5188670B2 (ja) 徐放性組成物およびその製造法
JP2004155792A (ja) 徐放性組成物およびその製造法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09043913

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase